Colorectal Cancer Research

Colorectal cancer (CRC) development typically follows the well-characterized adenoma-carcinoma sequence, a stepwise progression driven by the sequential accumulation of genetic and epigenetic alterations. Central to CRC pathology is the canonical Wnt/β-catenin signaling pathway, which is dysregulated in over 90% of cases, primarily through the inactivation of the APC tumor suppressor gene. This disruption leads to the stabilization and nuclear accumulation of β-catenin, initiating a transcriptional program that promotes cell proliferation and dedifferentiation. Furthermore, the integrity of DNA Mismatch Repair (MMR) proteins (MSH2, MSH6, MLH1, PMS2) is a critical diagnostic and prognostic determinant. A deficiency in these proteins (dMMR) fails to correct replication errors, leading to high microsatellite instability (MSI-H). This "mutator phenotype" is not only a hallmark of hereditary Lynch syndrome but also a powerful predictor of sensitivity to immune checkpoint blockade due to increased neoantigen burden. In the clinical setting, established diagnostic markers like Carcinoembryonic Antigen (CEA) and epithelial adhesion molecules such as EPCAM remain pivotal for disease monitoring and histological confirmation.

The Microenvironment and Metabolic Rewiring

Scientific attention is increasingly turning towards the gut microbiome's intricate influence on CRC progression, particularly how dysbiosis—such as the enrichment of Fusobacterium nucleatum—can modulate the tumor immune microenvironment and promote chemoresistance. A major research focus is the stark contrast in the immune landscape between MSI-high tumors, which are typically "immune-hot" with dense T-cell infiltration, and microsatellite-stable (MSS) tumors, which often display an "immune-excluded" phenotype. Mechanistically, the nuclear translocation of β-catenin remains a key area of study for understanding the maintenance of cancer stem cell populations and the hijacking of crypt regeneration pathways. Additionally, the loss of MMR proteins is being investigated beyond diagnosis, serving as a determinant of high tumor mutational burden (TMB) and neoantigen load, which actively recruits tumor-infiltrating lymphocytes (TILs). Furthermore, translational research is vigorously exploring the utility of CEA and EPCAM in liquid biopsy platforms, specifically for detecting circulating tumor cells (CTCs) to identify minimal residual disease and monitor early recurrence dynamics.

Robust Reagents for GI Cancer Research

Creative Biolabs offers a premium collection of antibodies tailored for colorectal cancer investigation. We provide highly specific antibodies for the complete MMR panel (MSH2, MSH6, MLH1, PMS2), essential for identifying dMMR status. Our range includes sensitive detection tools for nuclear β-catenin, EPCAM, and CEA, facilitating comprehensive phenotypic analysis. By ensuring rigorous validation for immunohistochemistry, Creative Biolabs enables researchers to accurately assess the molecular features of CRC, supporting studies into genomic instability and Wnt pathway dysregulation.

Product List